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Objectives The aim of this study was to determine whether nitrogen-containing bisphosphonate (NCBP) therapy is associ-
ated with the prevalence of cardiovascular calcification.
Background Cardiovascular calcification correlates with atherosclerotic disease burden. Experimental data suggest that NCBP
might limit cardiovascular calcification, which has implications for disease prevention.
Methods The relationship of NCBP use to the prevalence of aortic valve, aortic valve ring, mitral annulus, thoracic aorta, and
coronary artery calcification (AVC, AVRC, MAC, TAC, and CAC, respectively) detected by computed tomography was
assessed in 3,710 women within the MESA (Multi-Ethnic Study of Atherosclerosis) with regression modeling.
Results Analyses were age-stratified, because of a significant interaction between age and NCBP use (interaction p val-
ues: AVC p  0.0001; AVRC p  0.0001; MAC p  0.002; TAC p  0.0001; CAC p  0.046). After adjusting for
age; body mass index; demographic data; diabetes; smoking; blood pressure; cholesterol levels; and statin, hor-
mone replacement, and renin-angiotensin inhibitor therapy, NCBP use was associated with a lower prevalence of
cardiovascular calcification in women 65 years of age (prevalence ratio: AVC 0.68 [95% confidence interval
(CI): 0.41 to 1.13]; AVRC 0.65 [95% CI: 0.51 to 0.84]; MAC 0.54 [95% CI: 0.33 to 0.93]; TAC 0.69 [95% CI: 0.54
to 0.88]; CAC 0.89 [95% CI: 0.78 to 1.02]), whereas calcification was more prevalent in NCBP users among the
2,181 women 65 years of age (AVC 4.00 [95% CI: 2.33 to 6.89]; AVRC 1.92 [95% CI: 1.42 to 2.61]; MAC 2.35
[95% CI: 1.12 to 4.84]; TAC 2.17 [95% CI: 1.49 to 3.15]; CAC 1.23 [95% CI: 0.97 to 1.57]).
Conclusions Among women in the diverse MESA cohort, NCBPs were associated with decreased prevalence of cardiovascular
calcification in older subjects but more prevalent cardiovascular calcification in younger ones. Further study is
warranted to clarify these age-dependent NCBP effects. (J Am Coll Cardiol 2010;56:1752–9) © 2010 by the
American College of Cardiology Foundation
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November 16, 2010:1752–9 Bisphosphonates and Cardiovascular Calcificationtherosclerosis is a systemic disease frequently associated
ith calcification of the aorta, coronary and peripheral
rteries, and left heart valves through an active process that
esembles bone formation (1–5). Calcification at each ana-
omic site is a marker of atherosclerotic disease burden that
s independently associated with increased morbidity and
ortality (6–9).
Experimental data from animal models and patients on
ong-term hemodialysis suggest that nitrogen-containing
isphosphonates (NCBPs) (e.g., ibandronate, alendronate,
isedronate, and zoledronate) might limit vascular and
alvular calcification (10–12). Bisphosphonates are primar-
ly used in the management of osteoporosis to prevent
steoclast-mediated bone resorption by binding to hydroxy-
patite (13). Nitrogen-containing bisphosphonates inhibit
arnesyl-pyrophosphate synthase, an enzyme in the meval-
nate pathway distal to 3-hydroxy-3-methyl-glutaryl-CoA
eductase, the site of statin action (14). Consequently,
everal pharmacological effects are common to both NCBPs
nd statins. The NCBPs decrease serum low-density li-
oprotein (LDL) cholesterol levels by approximately 5%,
aise high-density lipoprotein (HDL) cholesterol by 10% to
8% (15,16), and reduce inflammation by inhibiting the
ecretion of several inflammatory cytokines (17,18). How-
ver, NCBP inhibition of vascular and valvular calcification
ight alternatively be secondary to prevention of bone
esorption and the subsequent release of calcium phosphate
articles from bone (11). Recent data suggesting that
CBPs and other osteoporosis therapies might slow the
rogression of aortic stenosis support this hypothesis (19).
hus, NCBPs might provide a unique and novel means to
low cardiovascular calcification.
Despite experimental evidence that NCBPs might mod-
late cardiovascular calcification, clinical efficacy in this
egard has not been assessed in patients with subclinical
ardiovascular disease. We present the first evaluation of the
elationship between NCBPs and the prevalence of cardio-
ascular calcification in women without recognized cardio-
ascular disease within a multiethnic, community-based
ohort.
ethods
tudy population and data collection. The MESA
Multi-Ethnic Study of Atherosclerosis) is a National
eart, Lung, and Blood Institute–sponsored longitudinal
ohort study of 6,814 community-dwelling men and women
ge 45 to 84 years without evidence of clinical cardiovascular
isease recruited from 6 U.S. communities (Forsyth
ounty, North Carolina; Northern Manhattan and the
ronx, New York; Baltimore County, Maryland; St. Paul,
innesota; Chicago, Illinois; and Los Angeles County,
alifornia). Eligible subjects were sampled by self-reported
ace to generate an ethnically diverse cohort that was 38%
hite, 22% African American, 22% Hispanic, and 12%
sian. Participants were excluded if they carried a previous aiagnosis of cardiovascular dis-
ase. Participants attended study
isits that included physical ex-
mination, prescription medica-
ion review, and assessment of
ubclinical cardiovascular disease
y trained study staff with a va-
iety of noninvasive modalities
ccording to standardized proto-
ols. A complete description of
he design of the MESA study
as been published elsewhere
20).
Data for the present study
ere taken from the first exami-
ation of the cohort (July 2000 to
ugust 2002). This analysis was
onfined to the 3,710 women
nrolled in the MESA study,
ecause the overwhelming ma-
ority of subjects (93%) receiv-
ng NCBP therapy in the MESA
tudy are women.
easurement of vascular and
alvular calcification. Cardio-
ascular calcification was assessed
y electron-beam computed to-
ography (CT) at 3 centers and multi-detector row helical CT
t 3 centers. All studies were interpreted at a central reading
enter (Harbour–University of California at Los Angeles
esearch and Education Institute, Los Angeles, California).
ortic valve, aortic valve ring, mitral annulus, thoracic aorta,
nd coronary artery calcification (AVC, AVRC, MAC,
AC, and CAC, respectively) were quantified by the
gatston scoring method (21). Detectable calcium was
efined as a score of 0 Agatston units (AU); a minimum
ocus of calcification was based on at least 4 contiguous
oxels, resulting in identification of calcium of 1.15 mm3
ith the multidetector CT scanners (0.68  0.68  2.50
m) and 1.38 mm3 with the electron-beam CT scanners
0.68  0.68  3.00 mm). Details of the image acquisition
nd interpretation protocols, quality control measures, and
nterobserver reliability characteristics have been reported
22,23).
Aortic valve calcification was defined as any calcified
esion within the aortic valve leaflets. Aortic valve ring
alcium was measured at the level of the aortic ring. Mitral
nnulus calcification was differentiated from that in the
ircumflex artery. Thoracic aorta calcification was quantified
n the segment of the descending aorta imaged during
ardiac CT. Coronary calcification was measured along the
natomic course of the coronary arteries.
CBP therapy. A validated medication inventory was
sed to assess medication use (24). Subjects were asked to
ring all prescribed and over-the-counter medication pack-
Abbreviations
and Acronyms
AU  Agatston units
AVC  aortic valve
calcification
AVRC  aortic valve ring
calcification
BMD  bone mineral
density
CAC  coronary artery
calcification
CI  confidence interval
CT  computed
tomography
HDL  high-density
lipoprotein
LDL  low-density
lipoprotein
MAC  mitral annulus
calcification
NCBP  nitrogen-
containing bisphosphonate
PR  prevalence ratio
TAC  thoracic aorta
calcificationges to each MESA visit, where trained study personnel
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Bisphosphonates and Cardiovascular Calcification November 16, 2010:1752–9ecorded the names and dosages. The NCBP therapy was
efined by the use of any oral or intravenous NCBP, such as
bandronate, alendronate, risedronate, and zoledronate on
he date of their cardiac CT scan.
ovariate measurements. Standardized questionnaires
ere used to collect data on age, sex, ethnicity, and
edical history. Information regarding physical activity
as collected with a combination of self-administered
nd interviewer-administered questionnaires. Smoking
tatus was defined as current, former, or never with
urrent smoking defined as having smoked a cigarette in
he last 30 days. Diabetes was defined as a fasting glucose
126 mg/dl or by the use of a hypoglycemic medication.
ypertension was defined as a systolic blood pressure
140 mm Hg or diastolic blood pressure 90 mm Hg or
y the use of medication prescribed for hypertension.
lood pressure was measured 3 times in the seated
osition with a Dinamap model Pro 100 automated
scillometric sphygmomanometer (Critikon, General
lectric, Madison, Wisconsin). The average of the sec-
nd and third readings was recorded. Serum lipid levels
ere measured from blood samples obtained after a 12-h
ast. The LDL cholesterol was calculated with the
riedewald equation (25).
tatistical analysis. Characteristics of the participants, in-
luding demographic data, medical history, and serologic
est results, were evaluated according to NCBP use. Differ-
nces in characteristics across NCBP use were determined
ith the Student t test for normally distributed continuous
ariables, the Wilcoxon Mann-Whitney 2-sample test for
ontinuous variables not normally distributed, and chi-
quare test for categorical variables.
The primary outcomes for this analysis were the preva-
ences of AVC, AVRC, MAC, TAC, and CAC 0 AU at
nitial CT scan evaluation. Relative risk regression was used
o model prevalence ratios (PR) assessing the relationships
etween NCBP use and baseline prevalence of AVC,
VRC, MAC, TAC, and CAC, adjusting for identified
onfounders with robust variance estimation (26). To in-
orporate severity of calcification into our analyses, we
ogarithmically transformed calcification scores (natural log
AU 1]) to normalize their distribution. Linear regression
odels using log (AU  1) as the dependent variable were
hen used to assess associations with NCBP use while
djusting for potential confounders. Covariates potentially
elated to vascular and valvular calcification were selected for
nclusion in multivariable models a priori. Interactions were
ested for as multiplicative terms in the statistical models
nly for the main effects (NCBP use and calcification).
hen an interaction was detected, the results were reported
s a stratified analysis. We used multiple imputation tech-
iques to adjust for missing data in 2% of subjects. Statis-
ical analyses were performed with SAS version 9.1.3 (SAS
nstitute, Inc., Cary, North Carolina) with significance
ccepted at p  0.05. Prevalence ratios are reported with
5% confidence intervals (CIs). besults
ubject characteristics. A total of 3,710 female MESA
articipants were included. The mean age was 63 years
range 45 to 84 years), and mean body mass index was 29 
kg/m2. Of this cohort, 1,411 (38%) were white, 1,025
28%) were black, 814 (22%) were Hispanic, and 460 (12%)
ere Chinese. The medical history included diabetes in 481
13%), hypertension in 1,529 (41%), hyperlipidemia in
,532 (41%), current tobacco use in 415 (11%), and past
obacco use in 1,086 (29%). Five hundred ninety-eight were
aking lipid-lowering medication (16%), and 1,253 (34%)
ere taking antihypertensive medication. The mean systolic
lood pressure was 127  23 mm Hg, and diastolic blood
ressure was 68 10 mm Hg. The mean fasting total serum
holesterol was 200  36 mg/dl, LDL cholesterol was
17  32 mg/dl, HDL cholesterol was 57  15 mg/dl, and
riglycerides were 128  71 mg/dl.
Two hundred fourteen subjects (6%) were receiving
CBP therapy at baseline (Table 1). The NCBP users were
n average older (67  8 years vs. 62  10 years; p 
.0001) and had lower body mass index (25  5 kg/m2 vs.
8  6 kg/m2; p  0.0001) than nonusers (n  3,423). A
reater proportion of NCBP users were receiving lipid-
owering medications compared with nonusers (21% vs.
aseline Characteristics Stratified by NCBP UseTable 1 Baseline Characteristics Stratified by NCBP Use
NCBP Users
(n  214)
Nonusers
(n  3,496) p Value
Age, mean (SD) yrs 67 (8) 62 (10) 0.0001
Race
White 126 (59) 1,285 (37) 0.0001
Black 33 (15) 992 (28)
Hispanic 24 (11) 790 (23)
Chinese 31 (14) 429 (12)
Serum cholesterol, mean (SD), mg/dl
Total cholesterol 198 (37) 200 (36) 0.55
LDL cholesterol 113 (33) 118 (32) 0.04
HDL cholesterol 59 (17) 56 (15) 0.0001
Triglycerides 120 (56) 128 (71) 0.04
Diabetes mellitus 20 (9) 461 (13) 0.12
Hyperlipidemia 100 (47) 1,432 (41) 0.12
Hypertension 80 (37) 1,449 (41) 0.41
Smoking status
Former 78 (36) 1,008 (29) 0.02
Current 17 (8) 398 (11) 0.12
Concurrent medication
RAS inhibitor 14 (7) 421 (12) 0.02
Beta-blocker 20 (9) 360 (10) 0.73
Calcium-channel blocker 33 (15) 471 (13) 0.41
Diuretic 35 (16) 633 (18) 0.58
Statin 42 (20) 527 (15) 0.08
Blood pressure, mean (SD), mm Hg
Diastolic 68 (10) 69 (10) 0.09
Systolic 125 (23) 127 (23) 0.40
alues given are n (%), unless otherwise specified.
HDL  high-density lipoprotein; LDL  low-density lipoprotein; NCBP  nitrogen-containing
isphosphonate; RAS  renin-angiotensin system.
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November 16, 2010:1752–9 Bisphosphonates and Cardiovascular Calcification6% p  0.06), whereas a smaller proportion were taking a
enin-angiotensin system inhibitor (7% vs. 12%, p  0.02).
erum LDL cholesterol levels were lower (113  33 mg/dl
s. 118  32 mg/dl; p  0.04), and HDL cholesterol levels
ere higher (61 17 mg/dl vs. 57 15 mg/dl; p 0.0001)
n NCBP-users than in nonusers.
elationship of bisphosphonate use to cardiovascular
alcification. The prevalences of AVC, AVRC, MAC,
AC, and CAC, defined as calcification scores 0 AU,
ere 11%, 34%, 11%, 29%, and 40%, respectively. The
revalences of AVRC and MAC were similar in NCBP
sers and nonusers (AVRC 38% vs. 34%; MAC 10% vs.
1%; respectively), but NCBP use was associated with more
revalent aortic valve and vascular calcification (AVC 15%
s. 10%; TAC 35% vs. 28%; CAC 47% vs. 40%).
Significant interactions between age and NCBP use were
bserved for each measure of cardiovascular calcification
interaction p values: AVC p 0.0001; AVRC p 0.0001;
AC p  0.002; TAC p  0.0001; CAC p  0.046).
onsequently, we age-stratified subsequent analyses of cal-
ification with the midpoint of the MESA age range.
ecause of the established differences in the prevalence and
everity of osteoporosis across ethnic groups (27), we also
ested for interactions between NCBP use and ethnicity
or each measure of calcification. No significant interac-
ions with race were detected for any of the calcification
easures in the entire cohort (interaction p values: AVC
 0.13; AVRC p  0.56; MAC p  0.95; TAC p 
.14; CAC p  0.21), in women 65 years of age (AVC
 0.75; AVRC p  0.66; MAC p  0.57; TAC p 
.24; CAC p  0.56), or in women 65 years of age
AVC p  0.14; AVRC p  0.66; MAC p  0.86; TAC
 0.74; CAC p  0.43).
Across all measures of cardiovascular calcification, the
ssociation with NCBP use (Table 2) varied with age. In
revalence of Valvular or Vascular Calcificationtratified by Bisphosph nate UseTable 2 Prevalence of Valvular or Vascular CalcificationStratified by Bisphosphonate Use
Calcification
Site
Bisphosphonate Users
(n  214)
Nonusers
(n  3,496) p Value
Aortic valve
Age 65 yrs 18 (18) 78 (4) 0.0001
Age 65 yrs 15 (13) 279 (20) 0.11
Aortic valve ring
Age 65 yrs 38 (38) 348 (17) 0.0001
Age 65 yrs 43 (38) 832 (59) 0.0001
Mitral annulus
Age 65 yrs 9 (9) 70 (3) 0.009
Age 65 yrs 13 (11) 303 (21) 0.01
Thoracic aorta
Age 65 yrs 31 (31) 224 (11) 0.0001
Age 65 yrs 43 (38) 766 (54) 0.0001
Coronary arteries
Age 65 yrs 36 (36) 516 (25) 0.02
Age 65 yrs 65 (57) 885 (63) 0.27
alues given are n (%). Prevalent calcification defined as a calcification score 0 Agatston units.emale subjects age 65 years, NCBP use was associated
s
sith less prevalent cardiovascular calcification (NCBP users
s. nonusers: AVC 13% vs. 20%, p  0.11; AVRC 38% vs.
9%, p  0.0001; MAC 11% vs. 21%, p  0.01; TAC 38%
s. 54%, p  0.0001; CAC 57% vs. 63%, p  0.27). In
ontrast, cardiovascular calcification was more prevalent in
CBP users younger than 65 years (AVC 18% vs. 4%, p 
.0001; AVRC 38% vs. 17%, p 0.0001; MAC 9% vs. 3%,
 0.009; TAC 31% vs. 11%, p  0.0001; CAC 36% vs.
5%, p  0.02).
Multivariate regression models adjusting for age, body
ass index, ethnicity, education, income, health insurance
tatus, physical activity, study site, smoking, systolic and
iastolic blood pressure, LDL and HDL cholesterol levels,
iabetes mellitus, hypertension, and statin, hormone re-
lacement, and renin-angiotensin inhibitor therapy simi-
arly demonstrated that NCBP correlates were age-
ependent. Among 1,498 women 65 years of age, NCBP
se was associated with a lower prevalence ratio of cardio-
ascular calcification (Table 3) (AVC PR: 0.68, 95% CI:
.41 to 1.13, p  0.14; AVRC PR: 0.65, 95% CI: 0.51 to
.84, p  0.0008; MAC PR: 0.54, 95% CI: 0.33 to 0.93,
 0.02; TAC PR: 0.69, 95% CI: 0.54 to 0.88, p  0.003;
AC PR: 0.89, 95% CI: 0.78 to 1.02, p  0.09). In
ontrast, NCBP use was associated with a higher prevalence
atio of calcification at each anatomic site in the 2,181
emale subjects 65 years of age (Table 3) (AVC PR: 4.00,
5% CI: 2.33 to 6.89, p  0.0001; AVRC PR: 1.92, 95%
I: 1.42 to 2.61, p 0.0001; MAC PR: 2.35, 95% CI: 1.12
o 4.84, p  0.02; TAC PR: 2.17, 95% CI: 1.49 to 3.15, p
0.0001; CAC PR: 1.23, 95% CI: 0.97 to 1.57, p 0.09).
iner grouping by 10-year age strata demonstrated a gradual
eduction in NCBP-associated calcification with increasing age,
espite adjusting for the aforementioned confounders (Fig. 1).
revalence Ratio for Vascular and Valvularalcification W th Bisphosphonate Usetratified by Age
Table 3
Prevalence Ratio for Vascular and Valvular
Calcification With Bisphosphonate Use
Stratified by Age
Calcification
Site
Prevalence
Ratio
95% Confidence
Interval p Value
Interaction With Age
p Value
Aortic valve 0.0001
Age 65 yrs 4.00 2.33–6.89 0.0001
Age 65 yrs 0.68 0.41–1.13 0.14
Aortic valve ring 0.0001
Age 65 yrs 1.92 1.42–2.61 0.0001
Age 65 yrs 0.65 0.51–0.84 0.003
Mitral annulus 0.002
Age 65 yrs 2.35 1.12–4.84 0.02
Age 65 yrs 0.54 0.33–0.93 0.02
Thoracic aorta 0.0001
Age 65 yrs 2.17 1.49–3.15 0.0001
Age 65 yrs 0.69 0.54–0.88 0.003
Coronary arteries 0.046
Age 65 yrs 1.23 0.97–1.57 0.09
Age 65 yrs 0.89 0.78–1.02 0.09
odels adjust for age, body mass index, ethnicity, study site, education, income, health insurance
tatus, diabetes, hypertension, smoking, physical actively, blood pressure, serum cholesterol,
tatin therapy, and use of renin-angiotensin system inhibitors and hormone replacement therapy.
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Bisphosphonates and Cardiovascular Calcification November 16, 2010:1752–9he relationship of NCBP therapy to prevalent CAC followed
similar pattern but did not reach statistical significance.
imilar age-dependent relationships were noted between the
atural logarithm of calcification score plus 1 and NCBP use at
ach anatomic site such that calcification was more significant
n younger NCBP users compared with nonusers but less
ignificant in older NCBP users compared with nonusers
Figs. 2A to 2E). We observed no consistent relationship
etween NCBP use and the severity of cardiovascular calcifi-
ation alone. To eliminate the possibility of residual confound-
ng by statin use, we performed parallel analyses of the
revalence of cardiovascular calcification stratified by statin use.
lthough power was diminished by this added stratification,
ffect measures were consistent.
iscussion
n this ethnically diverse cohort of women, we demonstrated
obust and consistent relationships between the prevalence
f cardiovascular calcification and NCBP use. We found a
lear interaction of NCBP use with age such that there was
Figure 1 Bisphosphonate-Associated Prevalence Ratio of Cardi
The prevalence ratio of cardiovascular calcification associated with nitrogen-contai
becomes significantly reduced in elderly persons. Models adjust for age, body mas
sion, smoking, physical activity, blood pressure, serum cholesterol levels, and staeduced prevalence of vascular and valvular calcification in vomen age 65 years and increased prevalence of cardio-
ascular calcification in younger women on treatment. Finer
ge stratification supported a gradual transition of risk with
ncreasing age.
Independent data from the MESA study and other
bservational studies have associated osteoporosis with car-
iovascular calcification (28–30). However, the mechanisms
esponsible for the inverse relationship between cardiovas-
ular calcification and bone mineral density (BMD) are not
nown. In cell culture models, valve and bone cell types
espond in opposite ways to statins, with reduced calcifica-
ion in aortic valve myofibroblasts and augmented calcifica-
ion in a pre-osteoblast cell line (31). Similar effects have
een demonstrated in response to inflammatory cytokines
nd oxidized LDL in other models of vascular and bone
alcification (30,32). Among the proposed explanations for
his paradox is that chronic inflammation in response to
xidized LDL modulates calcification differently in vascular
issue and in bone, resulting in tandem calcification of soft
issue and softening of calcified tissues (30). These obser-
ular Calcification Stratified by Age
isphosphonate use is increased in young patients but decreases with age and
x, ethnicity, study site, education, income, health insurance, diabetes, hyperten-
rmone replacement, and renin-angiotensin inhibitor therapy.ovasc
ning b
s inde
tin, hoations suggest that NCBPs, which lead to increases in
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November 16, 2010:1752–9 Bisphosphonates and Cardiovascular CalcificationMD, might be inversely associated with cardiovascular
alcification.
The NCBPs have the potential to influence calcium
omeostasis in cardiovascular tissue by several mechanisms.
he NCBPs exert pleiotropic, statin-like effects that include
nhibition of protein prenylation (14), various inflammatory
rocesses (14,17,33), and vitamin K metabolism (11), each
f which has been associated with atherosclerotic disease
3,11,31,34–36). Inhibition of isoprenoid synthesis, which
s required for vitamin K metabolism, affects several vitamin
-dependent bone regulatory proteins, such as osteocalcin
nd matrix Gla protein (11,37). The NCBPs inhibit secre-
ion of interleukin 1-beta, interleukin-6, tumor necrosis
Figure 2 Relationship of NCBP Use to Log (Agatston Scores 
(A to E) Relationship of nitrogen-containing bisphosphonate (NCBP) use to log (Ag
be associated with higher log (Agatston score  1) in younger subjects but lower
NCBP use seems to be associated with an attenuated age-dependent increase in
fication in bone and cardiovascular (CV) tissues and the proposed effects of NCBP
advancing age in concert with lessening bone mineral density. The NCBPs might a
patients with osteoporosis, their use serves as a marker for those with low bone m
subjects.actor-alpha, and several matrix metalloproteinases in a dariety of cell types and reduce numbers of circulating
onocytes and tissue macrophages at the time of vascular
njury (17,18,33). The NCBPs might also reduce serum
ipids, which accumulate in vessel walls and valve leaflets
riggering calcification (15,16). Alternatively, cardiovascular
ffects of NCBPs might be related to selective inhibition of
one resorption by which calcium-phosphate mineral com-
lexes released into the bloodstream are deposited in vas-
ular and valvular tissues (11). Hence, although the effects
f NCBPs might be similar to statins in some respects, the
drug classes might have disparate actions mediated by
ffects on bone metabolism.
In a recent retrospective analysis of echocardiographic
nd Theoretical Schematic
scores  1) at each anatomic site is age-dependent. The NCBP use seems to
atston score  1) in older subjects when compared with NCBP nonusers. Thus
atston score  1). (F) Theoretical schematic demonstrating relationship of calci-
e and CV calcification are inversely related. CV calcification increases with
te both of these processes. Because NCBPs are prescribed predominantly for
l density and the associated increased risk of CV calcification seen in younger1) a
atston
log (Ag
log (Ag
s. Bon
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isphosphonates, calcitonin, or estrogen receptor modula-
ors for osteoporosis was associated with a mean annual
hange in aortic valve area of 0.10  0.18 cm2 compared
ith 0.22  0.22 cm2 in those not receiving these
edications (p  0.03). Our findings in subjects 65 years
f age lend support to this previous report and suggest that
he observed effects on progression of aortic stenosis might
e due to modulation of calcification within the cardiovas-
ular system and broaden the potential impact of bisphos-
honate drugs to include direct or indirect effects on aortic,
oronary artery, and mitral valve calcification.
We found a surprising association of NCBP use with
ncreased prevalence of cardiovascular calcification in those
ubjects younger than 65 years of age. Although the reasons
or this relationship are elusive, there are several possible
xplanations. First, low BMD has been associated with
ncreased risk of cardiovascular calcification (28–30). Given
hat NCBP therapy is prescribed predominantly for patients
ith osteoporosis, treatment might identify a group of
atients in whom an increased risk of cardiovascular calci-
cation is associated with low BMD (Fig. 2F). With age
nd presumably longer duration of NCBP use, the putative
rotective effect of these agents might overcome BMD-
ssociated cardiovascular risk, thereby reversing the associ-
tion. Previous data from the MESA study demonstrated
hat, compared with those women in the highest quartile of
one density, those in the lowest quartile displayed a
odestly increased risk of prevalent CAC (adjusted PR:
.16, 95% CI: 0.96 to 1.41) but no difference in risk of
revalent aortic calcification (adjusted PR: 1.02, 95% CI:
.93 to 1.12) (28). These effects were smaller in magnitude
han those that we observed with NCBP use, suggesting
hat NCBPs might exert a direct cardiovascular effect
eyond modulating BMD. Alternatively, bisphosphonate
se in younger women might be a marker for another
isease. The U.S. Preventive Services Task Force recom-
ends screening post-menopausal women beginning at age
0 years for osteoporosis if they are at increased risk and
outinely for those over 65 years of age (38). As such,
omen who warrant therapy at a young age possess a more
ggressive form of osteoporosis, secondary osteoporosis, or
ther diseases that place them at higher risk of cardiovas-
ular calcification. Lastly, a true age-dependent mechanism
f NCBP action or of the relationship between osteoporosis
nd atherosclerosis remains. Further clarification of the
bserved age-dependent associations between NCBP use
nd cardiovascular calcification requires knowledge of indi-
ation for NCBP use and duration of use, neither of which
ere available for this analysis. Future evaluations of NCBP
ffects on cardiovascular calcification are warranted, with
articular attention to age, indication for NCBP, and
uration of use.
Our findings suggest that NCBPs might modulate car-
iovascular calcification, a surrogate marker for atheroscle-
osis and cardiovascular outcomes. Whether attenuation of pardiovascular calcification alone, without interruption of
he underlying atherosclerotic process, improves cardiovas-
ular morbidity and mortality remains controversial (39).
he NCBPs might attenuate elements of the atherosclerotic
rocess through several pleiotropic effects (11,15–18,33),
ut further study is needed to elucidate the clinical impact of
hese effects. Unfortunately, randomized trials evaluating
CBPs have not reported cardiovascular events until re-
ently. The HORIZON (Health Outcomes and Reduced
ncidence with Zoledronic Acid Once Yearly) Recurrent
racture Trial, a randomized trial evaluating the benefits
nd safety of zoledronate therapy after low-trauma hip
racture, provides the most substantial supportive evidence
40). Annual intravenous administration of zoledronate was
ssociated with a trend toward reduced cardiovascular mor-
ality compared with placebo (3.4% vs. 4.9%; p  0.10). No
uch effect was suggested among patients enrolled in the
ORIZON Pivotal Fracture Trial who had not experi-
nced prior hip fracture (41). Additional studies are needed
o specifically address the effects of NCBP use on cardio-
ascular morbidity and mortality.
Given our cross-sectional study design; lack of serological
ata on levels of calcium, phosphate, parathyroid hormone,
itamin D, and various inflammatory markers; and unavail-
bility of data on duration of NCBP use, the effects of
CBP use on cardiovascular calcification cannot be defined
echanistically. Moreover, the relatively good health of the
ESA cohort limits our ability to evaluate the development
r progression of cardiovascular calcification over time.
espite these limitations, the robust and consistent associ-
tions between NCBPs and vascular and valvular calcifica-
ion within a cohort of relatively healthy women highlight
he need for further study of the effect of NCBPs on
ardiovascular calcification and to explore their therapeutic
otential. Additional studies are needed to elucidate the
echanisms involved and to evaluate whether NCBPs
ight exert harmful effects in younger women.
In summary, this study suggests an association between
CBP drug therapy and valvular, aortic, and coronary
rterial calcification in women with subclinical cardiovascu-
ar disease. Given similarities between the effects of NCBP
nd statin agents on lipid metabolism and protein prenyla-
ion and the beneficial effects of NCBPs on bone metabo-
ism, these drugs warrant further investigation as potential
herapeutic agents in elderly women prone to calcific car-
iovascular disease. It is also important to determine
hether an apparently detrimental increase in the preva-
ence of cardiovascular calcification in younger women
eflects heightened cardiovascular risk associated with os-
eoporosis (a toxic effect of this type of medication) or other
ge-dependent processes.
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